Ülo Palm (Secretary and Oversight Committee Chair)
Senior Vice President, Drug Development Operations, Allergan
Ülo Palm, MD, PhD, MBA, is currently Senior Vice President Drug Development Operations with Allergan Pharmaceuticals. Prior to Allergan, he was the SVP Clinical Operations & Biometrics and Therapeutic Area Head Respiratory Clinical Development with Forest Labs. Before joining Forest, Dr. Palm held the positions of Global Head Laboratory & Preclinical Quality Assurance and Global Head Clinical Operations Oncology with Novartis Pharmaceuticals. Prior to Novartis, Dr. Palm worked with Schering-Plough and Bayer in different operational and medical drug development functions. He has a total of 27 years of experience in the pharmaceutical industry.
Dr. Palm earned his M.D. (Internal Medicine, Neurology, Surgery) from the University of Berlin, Germany, where he also received a postgraduate research training as a medical scientist. He completed his research training with a PhD. During this time he was also a teaching assistant who lectured medical students on respiratory, kidney, and heart physiology and pathophysiology. His scientific work focused on kidney and electrolyte physiology, biological rhythms and their mathematical analysis, as well as catheter related infections. He is author and co-author of a number of scientific articles in international journals and holder of two medical patents.
He earned his MBA degree with a major in Information Technology/Computer Sciences from the AKAD University for Applied Science in Rendsburg, Germany.
Dr. Palm is a Senior Member of the American Society for Quality (ASQ) and a certified Manager of Quality and Organizational Excellence (ASQ-CMQ/OE). His work at the ASQ includes initiating and co-authoring the ASQ report on “Best Quality Practices For Biomedical Research In Drug Development”. He also serves on the Board of Directors of ANAB, the ANSI-ASQ National Accreditation Board. He has been a member of the TransCelerate BioPharma Oversight Committee and several sub-committees since 2013. He was appointed chair of the TransCelerate Oversight Committee in December 2016.
Dr. Palm’s vision is to expedite drug development by linking top medical science to operational excellence and 21st century technology. He has published on this topic and is a frequent speaker at international conferences on strategies to cut drug development time and costs through process improvement and technology.